Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Maurice Driessen"'
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
Autor:
Peter McAllister, Lois Lamerato, Lynda J. Krasenbaum, Joshua M. Cohen, Krishna Tangirala, Stephen Thompson, Maurice Driessen, Julian Casciano, Zenobia Dotiwala, Alexander Mauskop
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-8 (2021)
Abstract Background Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for migraine prevention in adults. Real-world data on the effectiveness of fremanezumab are
Externí odkaz:
https://doaj.org/article/e6c3c26c5cab4ff2be1b3f2e864869c6
Autor:
Sabrina Mueller, Fraence Gottschalk, Antje Groth, Wilhelmine Meeraus, Maurice Driessen, Thomas Kohlmann, Thomas Wilke
Publikováno v:
Respiratory Research, Vol 19, Iss 1, Pp 1-12 (2018)
Abstract Background Real-world evidence (RWE) can inform patient management decisions, but RWE studies are associated with limitations. Linkage of different RWE data types could address such limitations by enriching data and improving scientific qual
Externí odkaz:
https://doaj.org/article/d15dc5393f0043eb9d5a6f81ac159143
Autor:
Dhvani Shah, Maurice Driessen, Nancy Risebrough, Timothy Baker, Ian Naya, Andrew Briggs, Afisi S. Ismaila
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 16, Iss 1, Pp 1-10 (2018)
Abstract Background Cost-effectiveness of once-daily umeclidinium bromide (UMEC) was compared with once-daily tiotropium (TIO) and once-daily glycopyrronium (GLY) in patients with chronic obstructive pulmonary disease (COPD) from a UK National Health
Externí odkaz:
https://doaj.org/article/9f617592621f49199211fa6da830622f
Autor:
Jessica Ailani, Handing Xie, Maurice Driessen, Mario Ortega, Yitong Wang, Verena Ramirez Campos, Sangtaeck Lim
Publikováno v:
Wednesday, April 26.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73f2b82bc9752d52e518ba58d5aa0a2c
https://doi.org/10.1212/wnl.0000000000203473
https://doi.org/10.1212/wnl.0000000000203473
Autor:
Afisi S. Ismaila, Andrew Briggs, Nancy Risebrough, V. Paly, Maurice Driessen, Necdet B Gunsoy, Ian Naya
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Victoria Federico Paly,1 Ian Naya,2 Necdet B Gunsoy,3 Maurice T Driessen,4 Nancy Risebrough,5 Andrew Briggs,6 Afisi S Ismaila7,81ICON Health Economics, ICON, Philadelphia, PA, USA; 2Global Respiratory Franchise, GSK, Brentford, Middlesex, UK; 3Value
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aefe89fe950ca8e3b810f08f5007e49e
http://europepmc.org/articles/PMC6524132
http://europepmc.org/articles/PMC6524132
Autor:
Tim Baker, Dhvani Shah, Afisi S. Ismaila, Maurice Driessen, Ian Naya, Andrew Briggs, Nancy Risebrough
Publikováno v:
Respiratory Medicine. 145:130-137
Introduction The cost-effectiveness of long-acting muscarinic antagonist (LAMA) umeclidinium bromide (UMEC) 62.5 μg as add-on therapy to other maintenance COPD treatments is unknown. Methods This analysis assessed the cost-effectiveness of the follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4978f1d3f949d56965475446dce97174
https://doi.org/10.1016/j.rmed.2018.10.024
https://doi.org/10.1016/j.rmed.2018.10.024
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Introduction Chronic obstructive pulmonary disease (COPD) is an increasingly common cause of death worldwide. Its cardinal symptoms include breathlessness and severely reduced exercise capacity. Several patient-reported outcome (PRO) measures are use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9a726a37ff0707bc7a3a378b9bdfda5
https://doi.org/10.2147/copd.s100204
https://doi.org/10.2147/copd.s100204
Autor:
Afisi S. Ismaila, Nancy Risebrough, V. Paly, Maurice Driessen, Ian Naya, Necdet B Gunsoy, Andrew Briggs
Publikováno v:
Clinical Problems.
Introduction: Clinically important deterioration (CID) in COPD is a measure of meaningful short-term worsening in lung function, health status or a first acute exacerbation. The economic and quality of life (QoL) impact of avoiding CID is unclear. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::771326d5974e53801b475248126e7b34
https://doi.org/10.1183/13993003.congress-2018.oa1660
https://doi.org/10.1183/13993003.congress-2018.oa1660
Autor:
Tim Baker, Dhvani Shah, Afisi S. Ismaila, Maurice Driessen, Ian Naya, Andrew Briggs, Nancy Risebrough
Publikováno v:
Cost Effectiveness and Resource Allocation : C/E
Cost Effectiveness and Resource Allocation, Vol 16, Iss 1, Pp 1-10 (2018)
Cost Effectiveness and Resource Allocation, Vol 16, Iss 1, Pp 1-10 (2018)
Background Cost-effectiveness of once-daily umeclidinium bromide (UMEC) was compared with once-daily tiotropium (TIO) and once-daily glycopyrronium (GLY) in patients with chronic obstructive pulmonary disease (COPD) from a UK National Health Service
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8617ff88d6a75cd4a0548341bcb60f8
https://eprints.gla.ac.uk/163082/1/163082.pdf
https://eprints.gla.ac.uk/163082/1/163082.pdf
Autor:
Afisi S. Ismaila, Dhvani Shah, Andrew Briggs, Maurice Driessen, Ian Naya, Nancy Risebrough, Tim Baker
Publikováno v:
Ethic and Economics.
Introduction: The cost-effectiveness of treatments for chronic obstructive pulmonary disease (COPD) is needed. Objectives To evaluate the cost effectiveness of once-daily umeclidinium bromide 62.5 µg (UMEC) in combination with inhaled corticosteroid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::427283934f442b9b4277e9b2fea9c3a2
https://doi.org/10.1183/1393003.congress-2017.pa2789
https://doi.org/10.1183/1393003.congress-2017.pa2789